Isatuximab

Red

Brand Name(s):Sarclisa

Indication:Treatment of relapsed and refractory multiple myeloma in Adults

Rationale:1,2,3

Considered:Sep-20

Review Date:Sep-25

Comments:
Isatuximab, in combination with pomalidomide and dexamethasone, is licensed for treatment of adult patients with relapsed and refractory multiple myeloma who have received at least two prior therapies including lenalidomide and a proteasome inhibitor.